Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Hoth Therapeutics ( (HOTH) ) has shared an announcement.
On August 21, 2025, Hoth Therapeutics‘ board approved an employment agreement with Robb Knie, who will continue as CEO and President. The agreement includes a base salary, bonuses, and equity incentives, with provisions for termination and bonuses tied to company transactions. Additionally, on August 20, 2025, the company filed a patent application for HT-001, a topical formulation for managing side effects of cancer treatments, marking a significant step in its product development strategy.
The most recent analyst rating on (HOTH) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Hoth Therapeutics stock, see the HOTH Stock Forecast page.
More about Hoth Therapeutics
Hoth Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for dermatological disorders and conditions. The company is involved in creating topical formulations, such as HT-001, aimed at treating side effects from cancer treatment drugs.
Average Trading Volume: 1,168,496
Technical Sentiment Signal: Buy
Current Market Cap: $16.84M
Find detailed analytics on HOTH stock on TipRanks’ Stock Analysis page.